Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain; Quality of Life; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: morphine sulfate (Drug); quality-of-life assessment (Procedure)
Phase: Phase 2
Status: Completed
Sponsored by: Dana-Farber Cancer Institute Official(s) and/or principal investigator(s):
Nathaniel Katz, MD, Study Chair, Affiliation: Dana-Farber Cancer Institute
Summary
RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given
by mouth. It is not yet known if inhaled morphine is more effective than morphine given by
mouth in relieving breakthrough pain.
PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled morphine with that
of morphine given by mouth in treating cancer patients who have breakthrough pain.
Clinical Details
Official title: An Open Label, Randomized, Multicenter, Crossover, Phase II Study to Compare Pain Relief Following Morphine Administration Via AERxPMS vs Orally in Cancer Patients Experiencing Opioid-Sensitive Breakthrough Pain
Study design: Supportive Care
Detailed description:
OBJECTIVES: I. Compare the change in pain intensity during the 15 minutes immediately
following aerosolized vs oral morphine sulfate in cancer patients with opioid-sensitive
breakthrough pain. II. Compare preference for continued use of these regimens in these
patients. III. Compare the pain relief in patients treated with these regimens. IV. Evaluate
satisfaction of patients treated with these regimens.
OUTLINE: This is a randomized, open-label, crossover, multicenter study. Patients are
randomized to 1 of 2 treatment arms. Patients undergo titration of aerosolized morphine
sulfate over days 1-7 to determine the optimal baseline and breakthrough dosage. Arm I:
Patients receive aerosolized morphine sulfate as needed for breakthrough pain, up to 4
inhalations every 15 minutes, on days 8-14. Patients crossover to oral morphine sulfate as
needed for breakthrough pain on days 15-21. Arm II: Patients receive oral morphine sulfate as
needed for breakthrough pain on days 8-14. Patients crossover to aerosolized morphine sulfate
as needed for breakthrough pain, up to 4 inhalations every 15 minutes, on days 15-21.
Patients may continue treatment with either oral or aerosolized morphine sulfate for an
additional 60 days beginning on day 22. Quality of life is assessed weekly for 3 weeks.
Patients complete a pain management satisfaction survey at the end of each therapy crossover
week.
PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS: Opioid-sensitive breakthrough pain due to cancer More than 1
episode daily Oral opiate dose of no more than 100 mg of morphine No known allergy to
morphine or other opioids No known CNS excitatory response to morphine or other opioids No
unstable persistent morbidity due to prior chemotherapy or radiotherapy
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy:
More than 3 months Hematopoietic: Not specified Hepatic: Bilirubin less than 2. 0 mg/dL AST
less than 82 U/L ALT less than 72 U/L Renal: Creatinine less than 1. 5 mg/dL Pulmonary: No
significant history or recent exacerbation of bronchial asthma No chronic obstructive
pulmonary disease No significant pulmonary pathology that would preclude study Other: No
history of substance abuse, including alcohol, within the past 2 months No other condition
that would preclude study Not pregnant or nursing Fertile patients must use effective
contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Recovered from
prior chemotherapy No concurrent chemotherapy that would cause toxicity (e. g., emesis)
Endocrine therapy: Not specified Radiotherapy: Recovered from prior radiotherapy No
concurrent radiotherapy that would cause toxicity (e. g., emesis) Surgery: Not specified
Other: At least 30 days or 5 half-lives (whichever is longer) since prior investigational
drug No concurrent MAO inhibitors
Locations and Contacts
Brigham and Women's Hospital, Boston, Massachusetts 02115, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: March 2001
Last updated: May 23, 2008
|
